ArticleRMD open2024
Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs.
Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Inflammation and pain as interconnected targets in axial spondyloarthritis.Nature reviews. Rheumatology · 2026Review
- Early identification of difficult-to-manage axial spondyloarthritis using machine-learning decision trees.Therapeutic advances in musculoskeletal disease · 2026Article
- Psychosocial dimensions of pain in axial spondyloarthritis: Construct validity and responsiveness of the multidimensional pain inventory (MPI).Therapeutic advances in musculoskeletal disease · 2026Article
- Longitudinal Relationship Between Pain and Depression in People With Inflammatory Arthritis: A Narrative Review.Arthritis care & research · 2026Review
- The treatment landscape in axial spondyloarthritis-do we need new therapies?EULAR rheumatology open · 2025Review
- Article
- Understanding the causes of treatment failure is crucial for the management of axial spondyloarthritis.Nature reviews. Rheumatology · 2025Article
- [Chronic pain syndrome in musculoskeletal diseases-how different are fibromyalgia and long Covid?-Part 1].Zeitschrift fur Rheumatologie · 2025Review
- Resting-state functional connectivity between the frontoparietal network and the default mode network is aberrantly increased in ankylosing spondylitis.BMC musculoskeletal disorders · 2025Article
- Psychosocial burden of axial spondyloarthritis and impact of different disease domains: a systematic literature review.Rheumatology advances in practice · 2025Review
- Integrating nociplastic pain into neuropathic pain framework: a proposal for a revised classification.Frontiers in pain research (Lausanne, Switzerland) · 2025Review
- [Assessment of residual symptoms in patients with axial spondyloarthritis with low disease activity and analysis of its related factors].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2024Article
- Review
- Chronic Pain and Bone-Related Pathologies: A Narrative Review.Journal of pain research · 2024Review
- Early NGF-TrkA-CGRP signaling-related changes in dorsal root ganglia are associated with mechanical hypersensitivity in a zymosan A-induced SKG model prior to overt arthritis.Neurobiology of pain (Cambridge, Mass.)Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate the association of nociplastic (NoP) and neuropathic pain (NP) components with residual symptoms in patients with radiographic axial spondyloarthritis (r-axSpA) receiving biological disease-modifying antirheumatic drugs (bDMARDs).
methods78 patients with r-axSpA from the GErman SPondyloarthritis Inception Cohort receiving a bDMARD for at least 3 months were included in this analysis. The Widespread Pain Index (WPI) and the PainDETECT (PD) questionnaire were used to quantify the NoP and the NP components, respectively. Axial Spondyloarthritis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were used as measures of residual symptoms. C reactive protein (CRP) was used as a measure of systemic inflammatory activity. Univariable and multivariable regression analyses of disease activity were performed. The regions of the WPI score and items of the PD score were used for cluster analyses.
resultsLinear multivariable regression analysis showed that WPI and PD were independently associated with ASDAS (b=0.1, 95% CI 0.04 to 0.17, and b=0.05, 95% CI 0.02 to 0.08, respectively) and BASDAI (b=0.24, 95% CI 0.08 to 0.39, and b=0.17, 95% CI 0.1 to 0.25, respectively) in r-axSpA patients receiving stable treatment with bDMARDs. Furthermore, WPI and PD were found to be significantly associated with the presence of relevant residual symptoms as defined by BASDAI ≥4 (OR 1.93, 95% CI 1.09 to 4.15, and OR 1.32, 95% CI 1.04 to 1.85, respectively). The effects were present also in patients with normal level of CRP. Cluster analysis revealed three distinct pain distribution profiles and four specific sensory symptom constellations allowing differentiation of different pain subtypes.
conclusionBoth NoP and NP components seem to be associated with residual symptoms in patients with r-axSpA receiving treatment with bDMARDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.